These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31526209)

  • 1. Hip fractures following denosumab discontinuation: three clinical cases reports.
    Sosa Henríquez M; Gómez de Tejada Romero MJ; Escudero-Socorro M; Torregrosa Suau O
    J R Soc Med; 2019 Nov; 112(11):472-475. PubMed ID: 31526209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis.
    Tsuchiya K; Ishikawa K; Tani S; Oshita Y; Kuroda T; Yamamura R; Emori H; Maruyama H; Matsuoka A; Kudo Y; Shirahata T; Toyone T; Nagai T; Inagaki K
    Clin Interv Aging; 2019; 14():1445-1450. PubMed ID: 31496671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
    McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
    J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
    Cummings SR; Ferrari S; Eastell R; Gilchrist N; Jensen JB; McClung M; Roux C; Törring O; Valter I; Wang AT; Brown JP
    J Bone Miner Res; 2018 Feb; 33(2):190-198. PubMed ID: 29105841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
    Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
    Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second rebound-associated vertebral fractures after denosumab discontinuation.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab for Reducing Risk of Fractures in Postmenopausal Women.
    Song P; Zehtabchi S
    Am Fam Physician; 2019 May; 99(9):Online. PubMed ID: 31038897
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.